Cargando…

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders

In 2002, the first III generation antipsychotic drug was registered—aripiprazole. Its partial dopaminergic agonism underlies its unique mechanism of action and the potentially beneficial influence on the positive, negative, or cognitive symptoms. Due to its relatively high intrinsic activity, the dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siwek, Marcin, Wojtasik-Bakalarz, Krzysztof, Krupa, Anna Julia, Chrobak, Adrian Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046771/ https://www.ncbi.nlm.nih.gov/pubmed/36979208 http://dx.doi.org/10.3390/brainsci13030397

Ejemplares similares

Graph Analysis of Verbal Fluency Tests in Schizophrenia and Bipolar Disorder
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2022)

TED—trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder
por: Dudek, Dominika, et al.
Publicado: (2023)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2021)

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

TED—Trazodone Efficacy in Depression: A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs in Patients with a Depressive Episode—Preliminary Report
por: Siwek, Marcin, et al.
Publicado: (2023)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Psychopharmacology and Biological Studies of Psychosis
por: Siwek, Marcin, et al.
Publicado: (2023)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Altered Functional Connectivity Differences in Salience Network as a Neuromarker of Suicide Risk in Euthymic Bipolar Disorder Patients
por: Sobczak, Anna Maria, et al.
Publicado: (2020)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs
por: Woroń, Jarosław, et al.
Publicado: (2022)

Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs
por: Siwek, Marcin, et al.
Publicado: (2023)

Time-Frequency Characterization of Resting Brain in Bipolar Disorder during Euthymia—A Preliminary Study
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2021)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
por: Arai, Yusuke, et al.
Publicado: (2023)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

Machine Learning-Based Identification of Suicidal Risk in Patients With Schizophrenia Using Multi-Level Resting-State fMRI Features
por: Bohaterewicz, Bartosz, et al.
Publicado: (2021)

When practice does not make a perfect - paradoxical learning curve in schizophrenia and bipolar disorder revealed by different serial reaction time task variants
por: Chrobak, Adrian Andrzej, et al.
Publicado: (2023)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

Clozapine-Treatment-Resistant Schizophrenia Successfully Managed with Brexpiprazole Combination Therapy: Two Case Reports
por: Orsolini, L., et al.
Publicado: (2022)

Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials
por: Zhao, Mingjun, et al.
Publicado: (2022)

Pharmacological effects of berberine on mood disorders
por: Fan, Jie, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

PM384. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study
Publicado: (2016)

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder
por: Grant, Jon E., et al.
Publicado: (2022)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
por: Inada, Ken, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ao7d1gpu93jdpgethcv0m22j3a